DVAX
Dynavax Technologies Corp.
Halal Rating :
Last Price
$12.45
Last updated:
Market Cap
-
7D Change
-0.28%
1 Year Change
-12.24%
Company Overview
Industries
Exchange
Next Earnings Date
Dynavax Technologies Corporation is a biopharmaceutical company focused on developing and commercializing vaccines. The company's lead product is HEPLISAV-B, an adult hepatitis B vaccine. They also develop CpG 1018, a vaccine adjuvant used in various COVID-19 vaccines and other vaccine development programs.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $80.63m | $72.25m | - | $1.7m | 0.00% | 2.35% |
| June 30, 2024 | $73.8m | $70.3m | - | $1.7m | 0.00% | 2.42% |
| March 31, 2024 | $50.79m | $70.25m | - | $1.7m | 0.00% | 2.41% |
Company Impact
Help us evaluate Dynavax Technologies Corp.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.